AUTHORS
Audrey Lasry, Ph.D, Pier Edoardo Rovatti, Ph.D2, Bettina Nadorp, Ph.D3, Marta Casado-Peláez4, Deedra Nicolet, MS5, Abdullah M Ali, Research Scientist6, Aristotelis Tsirigos, PhD7, Manel Esteller, MD8, Martin Carroll, MD9, Ann-Kathrin Eisfeld, MD10, Azra Raza, MD11, Iannis Aifantis, PhD12
AFFILIATIONS
1 NYU Grossman School of Medicine, New York, United States
2 NYU Grossman School of Medicine, New York, United States
3 NYU Grossman School of Medicine, New York, United States
4 Josep Carreras Leukemia Research Institute, Barcelona, Spain
5 The Ohio State University Wexner Medical Center, Columbus, United States
6 Columbia University Medical Center, New York, United States
7 NYU Grossman School of Medicine, New York, United States, NYU Grossman School of Medicine, New York, United States
8 Sant Pau Research Institute (IRSantPau), Barcelona, Spain
9 Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
10 The Ohio State University Wexner Medical Center, Columbus, United States
11 Columbia University Medical Center, New York, United States
12 NYU Grossman School of Medicine, New York, United States
ABSTRACT
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor prognosis and poor responses to immunotherapy. We have previously shown that in AML, inflammation remodels the bone marrow (BM) immune microenvironment and is associated with expansion of immunosuppressive cell subsets, including atypical memory B cells (aMBC) and regulatory T cells (Treg). Here we investigate the role of aMBC in AML progression in murine models and patient samples and demonstrate that genetic blockade of aMBC development ameliorates disease phenotypes, enhances T activation, and alters immune architecture in the BM.
To identify disease subsets and clinical correlates that associate with aMBC accumulation, we examined the aMBC gene signature in RNA-Sequencing (RNA-Seq) data from the Alliance AML cohort (n=771 patients). aMBC were enriched in patients with myelodysplasia (MDS)-related AML (AML-MR) and were associated with poor overall survival and lower rates of complete remission. Analysis of single-cell RNA-Seq (scRNA-Seq) data from longitudinal BM aspirates of patients at MDS diagnosis and upon progression to AML (n=14 patients) demonstrated a gradual increase in aMBC levels as patients progress from MDS to AML. Furthermore, analysis of mice deficient in Tet2 (Tet2 KO), an established model of MDS and AML, also demonstrated a progressive enrichment in aMBC as mice progress through disease stages.
To examine the role of aMBC in disease progression, we crossed Tet2 KO mice to mice carrying a B cell-specific deletion of Tbx21, a key transcription factor for aMBC development and function (Tbx21-floxed/Cd19-Cre, Tbx21BKO). Tet2 KO/Tbx21BKO mice demonstrated an ameliorated disease phenotype, with smaller spleen size and reduction in extramedullary leukemic infiltrates to the spleen and liver, compared to Tet2 KO mice. scRNA-Seq analysis of the B cell compartment confirmed loss of aMBC in Tet2 KO/Tbx21BKO mice, and scRNA-Seq analysis of the T cell compartment revealed an expansion in cytotoxic and activated T cells in Tet2 KO/Tbx21BKO mice compared to Tet2 KO mice.
To identify mechanisms by which aMBC depletion may lead to enhanced T cell activation, we examined cell-cell communication data in our longitudinal MDS/AML patient cohort. Our analysis demonstrated that the major interaction partner for aMBC in MDS and AML are Treg, and the number of aMBC:Treg interaction increases as patients progress from MDS to AML. In line with this, Treg were enriched in MDS and AML patient BM in our scRNA-Seq data, and levels of Treg increased as patients progressed from MDS to AML. Furthermore, Treg acquire an activated gene expression profile with disease progression, indicating a functional role in mediating immune dysfunction in the BM. aMBC – Treg interaction was driven by HLA-II expression on aMBC, suggesting a physical interaction between aMBC and Treg in the BM.
To interrogate aMBC and T cell interactions in situ, we performed multiplex immunofluorescence on bone marrow sections from age-matched wild type (WT), Tet2 KO and Tet2 KO/Tbx21BKO mice. While in WT mice T and B cells were dispersed throughout the BM, in Tet2 KO mice T and B cells formed dense immune aggregates, enriched in CD4+ Foxp3+ Treg. In contrast, immune aggregates in Tet2 KO/Tbx21BKO mice were smaller (average size – Tet2KO: 25247.5um2 vs Tet2KO/Tbx21BKO: 11,728.9um2, p<0.0001) and contained less Treg (Tet2KO 4x10^-4/um2 vs Tet2KO/Tbx21BKO 2x10^-5/um2, p=0.0013), suggesting a switch in phenotype from immunosuppressive to immunopermissive. Analysis of BM core biopsies from AML-MR patients (n=12) revealed similar immune aggregates in 6/12 (50%) of patients, that are currently being examined using the 10x Xenium spatial transcriptomics platform. Furthermore, analysis of our scRNA-Seq data nominated therapeutic targets for aMBC and Treg depletion, including FCRL5, an aMBC-specific marker currently being investigated in multiple myeloma, and CD39, expressed on both aMBC and Treg, with clinical grade antibodies in clinical trials for different solid malignancies.
Overall, our data demonstrate a novel mechanism of B cell-mediated immune dysfunction in AML. We propose that B and T cell aggregates in the bone marrow of AML patients serve as hubs of T cell dysfunction, and that targeting aggregate components can enhance immune response to malignant cells. Our findings nominate atypical memory B cells as a novel target for immunotherapy in MDS and AML.
DISCLOSURES
Audrey Lasry, Ph.D: No relevant conflicts of interest to declare.